Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
  • Patent number: 11116784
    Abstract: Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: September 14, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Samir M. Parikh
  • Patent number: 11111288
    Abstract: This disclosure relates to a chimeric antigen receptor for binding with a tumor specific target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a parent protein or a fragment thereof and having a decrease in activity in the assay at the normal physiological condition compared to the activity in the assay under the aberrant condition. A method for producing the chimeric antigen receptor is also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 7, 2021
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11098117
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 24, 2021
    Assignee: Agenus Inc.
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
  • Patent number: 11085924
    Abstract: The present invention provides a method for evaluating the risk of occurrence of cancer in an individual.
    Type: Grant
    Filed: January 2, 2017
    Date of Patent: August 10, 2021
    Assignee: Syncerus S.À. R.L.
    Inventor: Jean-Francois Floch
  • Patent number: 11028129
    Abstract: In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 8, 2021
    Assignee: The Regents of the University of California
    Inventor: Alessandra Franco
  • Patent number: 11027014
    Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: June 8, 2021
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Lai-Ming Yung, Paul B. Yu
  • Patent number: 11001640
    Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
  • Patent number: 10994008
    Abstract: Methods of treating proliferative disorders are described. In particular, combination treatment with a GITR agonist and a PD-1 antagonist are provided.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 4, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Gu Danling, Amy M. Beebe
  • Patent number: 10975145
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: April 13, 2021
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Patent number: 10953105
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: March 23, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Darrell Irvine, Haipeng Liu
  • Patent number: 10941210
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 9, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas Macdonald
  • Patent number: 10912770
    Abstract: The invention relates to the use of adenosine monophosphate deaminase 2 (AMPD2) inhibitors alone or in combination with various agents to treat a wide variety of diseases including, but not limited to, sugar craving, salt craving, umami craving, and addictions including drug, tobacco, nicotine and alcohol addictions. Embodiments of the invention may also relate to stimulation of AMPD2 activity to treat anorexia nervosa or stimulate food intake in a subject.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 9, 2021
    Assignee: Regents of the University of Colorado, A Body Corporate
    Inventors: Richard J Johnson, Ana Andres Hernando, Miguel A Lanaspa Garcia
  • Patent number: 10906951
    Abstract: NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to add mutant (variant) TRAIL ligand expression.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 2, 2021
    Assignee: ONK THERAPEUTICS LIMITED
    Inventor: Michael Eamon Peter O'Dwyer
  • Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Patent number: 10858420
    Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 8, 2020
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 10829559
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: November 10, 2020
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
  • Patent number: 10822385
    Abstract: The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 3, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Jianhe Chen, Jesper F. Lau, Janos Tibor Kodra, Birgit Wieczorek, Lars Linderoth, Henning Thoegersen, Salka Elboel Rasmussen, Patrick William Garibay
  • Patent number: 10815305
    Abstract: The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: October 27, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jamie M. Orengo, Jeanne Allinne, Andrew J. Murphy, George D. Yancopoulos
  • Patent number: 10793622
    Abstract: The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Didier Duthe, Celine Hemet, Laure Landric-Burtin, Benoit Mothes
  • Patent number: 10783349
    Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 22, 2020
    Assignee: AXOGEN CORPORATION
    Inventor: Curt Deister
  • Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Patent number: 10745475
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: August 18, 2020
    Assignee: TAKEDA GMBH
    Inventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
  • Patent number: 10739352
    Abstract: A method of diagnosis or prediction of infection of a mammalian wound, said method comprising the step of detecting the presence of a cytokine selected from the group comprising procalcitonin, amino procalcitonin (N-ProCT), eotaxin, granulocyte macrophage colony stimulating factor (GM-CSF), interleukins IB monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a), regulated upon activation normal T expressed and secreted (RANTES) in fluid taken from the wound. Also claimed is the device for use in the method.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: August 11, 2020
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventors: Philip Godfrey Bowler, Samantha Alison Jones, Sarah Anne Welsby
  • Patent number: 10736900
    Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
  • Patent number: 10729769
    Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 4, 2020
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
  • Patent number: 10696738
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 30, 2020
    Assignee: Glaxon Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Patent number: 10683349
    Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 16, 2020
    Assignee: NOVARTIS AG
    Inventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
  • Patent number: 10683368
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisi
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ekkehard Moessner, Tilman Schlothauer
  • Patent number: 10656153
    Abstract: Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: PZM DIAGNOSTICS, LLC
    Inventor: Peilin Zhang
  • Patent number: 10640558
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 5, 2020
    Assignee: REGENERON PHAMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 10570199
    Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: February 25, 2020
    Assignee: KM Biologics Co., Ltd.
    Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
  • Patent number: 10526402
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Patent number: 10500252
    Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 10, 2019
    Assignee: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
    Inventors: Marc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
  • Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
  • Patent number: 10472425
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 12, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Patent number: 10464998
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 5, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • Patent number: 10441215
    Abstract: One embodiment includes an image acquisition circuit that accesses a pre-treatment and a post-treatment image of a region of tissue demonstrating non-small cell lung cancer (NSCLC), a segmentation and registration circuit that annotates the tumor represented in the images, and that registers the pre-treatment image with the post-treatment image; a feature extraction circuit that selects a set of pre-treatment and a set of post-treatment quantitative vessel tortuosity (QVT) features from the registered image; a delta-QVT circuit that generates a set of delta-QVT features by computing a difference between the set of post-treatment QVT features and the set of pre-treatment QVT features; and a classification circuit that generates a probability that the region of tissue will respond to immunotherapy based on the difference, and that classifies the region of tissue as a responder or non-responder. Embodiments may generate an immunotherapy treatment plan based on the classification.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: October 15, 2019
    Assignee: Case Western Reserve University
    Inventors: Anant Madabhushi, Yuanqi Xie, Vamsidhar Velcheti
  • Patent number: 10426797
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., United States of America as Represented by the Secretary, The Dept. of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10408847
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: September 10, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Urs Ochsner, David G. Sterling, Nebojsa Janjic
  • Patent number: 10400035
    Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 3, 2019
    Assignees: MedImmune, LLC, University of Helsinki
    Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
  • Patent number: 10400036
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Patent number: 10376582
    Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: August 13, 2019
    Assignee: Outlook Therapeutics, Inc.
    Inventors: John Cini, Athena Nagi, Maria Taddei
  • Patent number: 10376813
    Abstract: The present invention relates to a method for the determination of chromatography conditions for the separation of a biomolecule from a liquid sample, which method comprises selecting a number of experiments using design of experiments (DoE); performing said experiments with in-line conditioning of orthogonal quality measures; and based on the results from the experiments, determining efficient chromatography conditions for said biomolecule. The invention also relates to a system for performing the method as well as a computer program and an instrument comprising such a computer program.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 13, 2019
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Enrique Napoleon Carredano, Gustav Jose Rodrigo
  • Patent number: 10358498
    Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: July 23, 2019
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
  • Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Patent number: 10330670
    Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 25, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, JAPAN INNOVATION THERAPEUTICS, INC.
    Inventors: Hiroshi Matsuda, Akane Tanaka
  • Patent number: 10287345
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Patent number: 10273298
    Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: April 30, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Gesche Graf
  • Patent number: 10259859
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 16, 2019
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo